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ABSTRACT
Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are aggressive soft tissue
sarcomas that can occur sporadically or in the setting of the Neurofibromatosis
type 1 (NF1) cancer predisposition syndrome. These tumors carry a dismal overall
survival. Previous work in our lab had identified ATRX chromatin remodeler (ATRX),
previously termed, Alpha Thalassemia/Mental Retardation Syndrome X Linked as a
gene mutated in a subset of MPNSTs. Given the great need for novel biomarkers and
therapeutic targets for MPNSTs, we sought to determine the expression of ATRX in a
larger subset of sporadic and NF1 associated MPNSTs (NF1-MPNSTs). We performed
immunohistochemistry (IHC) on 74 MPNSTs (43 NF1-associated and 31 sporadic),
21 plexiform neurofibromas, and 9 atypical neurofibromas. Using this approach, we
have demonstrated that 58% (43/74) of MPNSTs have aberrant ATRX expression
(<80% nuclear expression) compared to only 7% (2/30) of benign (plexiform and
atypical) neurofibromas. Second, we demonstrated that 65% (28/43) of NF1-MPNSTs
displayed aberrant ATRX expression as did 48% (15/31) of sporadic MPNSTs. Finally,
we show that aberrant ATRX expression was associated with a significantly decreased
overall survival for patients with NF1-MPNST (median OS of 17.9 months for aberrant
expression and median OS not met (>120 months) for intact expression, p = 0.0276).
In summary, we demonstrate that ATRX is aberrantly expressed in the majority of
NF1-MPNSTs, but not plexiform or atypical neurofibromas. Additionally, aberrant
ATRX expression is associated with decreased overall survival in NF1-MPNST, but not
sporadic MPNST and may serve as a prognostic marker for patients with NF1-MPNST.
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INTRODUCTION

of protein expression. As such, loss of ATRX expression
is often thought of as a surrogate for mutational analysis.
Studies in other malignancies have shown a significant
correlation between ATRX mutational status and a mosaic
pattern of staining. For example 66% of pancreatic cancer
cases and 40% of gliomas with a mosaic staining pattern
had an identifiable ATRX mutation identified by nextgeneration sequencing [15, 17, 18]. It is possible that
another mechanism such as methylation changes lead to
silencing of ATRX expression in the other mosaic cases.
In the current study, we analyzed ATRX expression by
immunohistochemistry in 104 tumor samples (74 MPNST
samples from both sporadic and NF1 patients as well as
21 plexiform neurofibromas and 9 atypical neurofibromas)
from a total of 97 different patients. Of note, there are
104 tumors from 97 patients as seven patients had tissue
available from both their plexiform neurofibroma and the
subsequent MPNST that arose within the same anatomic
location.

Sarcomas are rare tumors that usually arise from
bone or soft tissue. Among soft tissue sarcomas, over
70 different subtypes exist. MPNSTs are aggressive
sarcomas that account for approximately 5% of all soft
tissue sarcomas [1]. Almost half of malignant peripheral
nerve sheath tumors (MPNSTs) occur sporadically (in
the absence of a tumor predisposition syndrome) or as
a complication of prior radiation therapy and the other
half occur in the setting of the Neurofibromatosis type 1
(NF1) tumor predisposition syndrome [2]. These tumors
are thought to be composed of malignant cells with
Schwannian differentiation, and in the setting of NF1
often arise from a benign precursor lesion, a plexiform
neurofibroma (benign neurofibroma involving multiple
fascicles of a peripheral nerve) or atypical neurofibromas
(benign neurofibroma with cytologic atypia, increased
cellularity, scattered mitotic figures, and/or loss of
neurofibroma architecture, albeit with a low mitotic index
of < 3/10 HPFs [3]). Even with multi-modality therapy,
the overall prognosis for MPNSTs is dismal with 50% of
patients failing to survive beyond five years of diagnosis
[4–6]. Prior genomic studies in our laboratory aimed at
identifying potential therapeutic targets and biomarkers
for MPNSTs had identified ATRX as a gene mutated in a
subset of MPNSTs [7].
ATRX is a member of the SWI/SNF family of
DNA helicases that plays a role in chromatin regulation
and maintenance of telomeres. It regulates incorporation
of histone H3.3 into telomeric chromatin [8, 9]. The
protein product is also implicated in the initiation of
non-homologous end joining (NHEJ) in gliomas [10]
, a process by which double strand DNA breaks (DSB)
are repaired. When disrupted, NHEJ deficiency results
in genome instability, cell cycle arrest, and/or cellular
death; however in tumor cell lines that lack cell cycle
checkpoints (e.g. p53 mutant), it can actually lead to
a mutator phenotype and promote tumor progression
[11]. The loss of ATRX function also contributes to
alternative lengthening of telomeres (ALT), a telomerase
independent mechanism of telomere lengthening leading
to cellular immortality, thus also promoting tumorigenesis
[12]. Further, ATRX is also known to direct members
of the polycomb repressor complex 2 (PRC2) to target
promoters and aid in heterochromatin formation and
epigenetic silencing, another way in which it may regulate
tumorigenesis [13].
Given the recent data suggesting a role for ATRX
in the pathogenesis and prognostication of GBM [14] and
other gliomas, [11, 15] including NF1-related gliomas
[16], and our recent data demonstrating ATRX mutations
in 2/7 MPNSTs sequenced cases [7], we sought to
determine whether or not ATRX expression was altered
in a larger subset of MPNSTs. Most reported mutations
in ATRX are inactivating mutations and thus lead to loss
www.oncotarget.com

RESULTS
We collected data and specimens from 104 tumors
including 74 MPNSTs, 9 atypical neurofibromas, and
21 plexiform neurofibromas coming from a total of 97
patients. Seven patients were represented in both the
plexiform neurofibroma group and the MPNST group.
Of the patients from the Washington University cohort
11/21 NF1-associated MPNSTs clearly arose from a
precursor plexiform or diffuse NF based on assessment
of the pathologic specimen. The other 10 NF1 patients
did not have imaging prior to their diagnosis of MPNST
and the tumor specimen consisted entirely of high grade
MPNST with no evidence of a pre-existing benign
component; these cases were assumed to have arisen
de novo. None of the sporadic MPNSTs showed any
evidence of a benign precursor in the pathologic
assessment (Table 1). This information is not available
for the UCSF cohort. Additionally, one sporadic MPNST
arose in an area of prior radiation treatment and none of
the NF1-associated MPNSTs in either cohort arose in
the area of prior radiation field (Table 1). Most patients
in this study were over the age of 18 years at diagnosis.
Of the patients with PNs (n = 21), 33% (7/21) were
prepubertal. As expected, only one (1/11) pediatric patient
developed an MPNST, and the rest of the pediatric patients
in the study had plexiform neurofibromas, as it is very
uncommon for an MPNST to present in childhood. The
median age at diagnosis was 34 years of age (23 years of
age for plexiform and atypical neurofibromas and 39 years
of age for MPNSTs). Approximately 2/3rds of the patients
had NF1 (43/74 MPNSTs, 7/9 atypical neurofibromas, and
21/21 plexiform neurofibromas) (Tables 2 and 3).
We next wanted to determine the ATRX expression
pattern in MPNSTs. MPNSTs fell into three groups
by immunohistochemical staining: retained, mosaic,
23019
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Table 1: The origin of MPNSTs
NF1-associated
11/21
0/21
10/21

Known plexiform NF precursor
Radiation induced
De novo

Sporadic
0/19
1/19
18/19

Data available only for the Washington University cohort (21 NF1-associated and 19 sporadic MPNSTs).
Table 2: Clinical characteristics of MPNST patients
Characteristic
Sex—no. (%)

ATRX positive (N = 31) ATRX mosaic (N = 29) ATRX negative (N = 14)

Total (N = 74)

Male
Female
Age at diagnosis—yr

13 (42)
18 (58)

12 (41)
17 (59)

8(57)
6 (43)

33 (45)
41 (55)

Median
Range
Age Category—no.
(%)
<18 yo
18 to 65 yo

38
18-79

39
22-71

36
11-58

39
11–79

0
27 (87)

0
28 (97)

2 (14)
12 (86)

2 (3)
67 (90)

4 (13)

1 (3)

0

5 (7)

15 (48)
16 (52)

18 (62)
11(38)

10 (71)
4 (29)

43 (58)
31(42)

>65 yo
NF Status—no. (%)
NF1
Sporadic

no = number, yr = year, NF = Neurofibromatosis.
Table 3: Clinical characteristics of atypical and plexiform neurofibromas
Characteristic
Sex—no. (%)
Male
Female
Age at diagnosis—yr
Median
Range
Age Category—no. (%)
<18 yo
18 to 65 yo
>65 yo
NF Status—no. (%)
NF1
Sporadic
Not Reported
Tumor Type—no.(%)
Atypical Neurofibroma
Plexiform Neurofibroma

ATRX positive (N = 28)

ATRX mosaic (N = 2)

Total (N = 30)

10 (36)
18 (64)

1 (50)
1 (50)

11 (37)
19 (63)

21
7–67

11
4–27

23
4–67

9 (32)
18 (64)

1 (50)
1 (50)

10 (33)
19 (63)

1 (4)

0

1 (4)

26 (93)
1 (3)

2 (100)
0

28 (94)
1 (3)

1 (3)

0

1 (3)

9 (32)
19 (68)

0
2 (100)

9 (30)
21 (70)

There were no ATRX negative patients in the above tumor types.
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or complete loss (Figure 1). This is similar to what has
been previously published in adult diffuse gliomas [15].
Of note, loss of ATRX staining has been associated with
ATRX mutational status [19] and mosaic staining has been
associated with ATRX mutations in approximately 40% of
cases [15]. As can be seen in Table 1, slightly more than
half of the MPNSTs (43/74 tumors) examined exhibited
either a mosaic pattern (29 tumors) or loss of ATRX (14
tumors). For 6 of the cases we did have sequencing data as
well. Of those cases 2/6 cases harbored a non-synonymous
mutation in ATRX and both of these cases exhibited a loss
of ATRX by IHC. There was no association with other
common genes mutated in MPNSTs in this small subset
(Supplementary Table 1).
We then examined whether aberrant ATRX protein
expression was also seen in plexiform and atypical
neurofibromas, known precursor lesions to MPNSTs.
Interestingly, only 7% (2/30) of plexiform neurofibromas
and atypical neurofibromas show aberrant ATRX protein
expression (Figure 2), compared to 57% (43/74) of
MPNSTs showing aberrant ATRX protein (Figure 3, p <
0.0001, Fisher’s Exact Test). Taken together, these data
suggest that changes in levels of ATRX are associated with
malignancy, rather than the pre-malignant state.

Finally, we wanted to determine whether or not
ATRX expression correlated with overall survival (OS).
MPNSTs with aberrant ATRX expression showed a trend
toward worse OS in comparison to MPNSTs with retained
ATRX expression, though statistically not significant
(Figure 4A, p = 0.2091, log rank test). However, when
we broke the cohort into NF1-MPNSTs and sporadic
MPNSTs, we did observe a statistically significant
decrease in OS for patients with NF1-MPNSTs who have
aberrant ATRX expression (Figure 4B, p = 0.0276, log
rank test), but there is no difference in overall survival
based on ATRX status for sporadic MPNSTs (Figure 4C,
p = 0.4570, log rank test). In a multivariate analysis of
NF1-MPNSTs which evaluated margin status, adjuvant
and neoadjuvant treatment, age, initial tumor size,
presence of metastasis at diagnosis, initial location of the
tumor, and gender, aberrant ATRX expression was found
to be an independent poor prognostic factor with a hazard
ratio of 5.3 (95%CI:1.367–20.433) (Table 4).

DISCUSSION
MPNSTs are aggressive sarcomas with limited
treatment options and poor overall survival. Furthermore,

Figure 1: MPNSTs show three distinct patterns of ATRX staining. Routine hematoxylin and eosin staining demonstrates typical

MPNST morphology. (A, C and E). ATRX nuclear staining in the tumor cells can be classified as retained (B, 81–100%), mosaic (D, 21–
80%), or negative (F, 0–20%). Note the residual ATRX nuclear staining in the inflammatory and endothelial cells in panel F as an internal
positive control. The mitotic indices are 62/10 HPFs (A and B), 6/10 HPFs (C and D), and 4/10 HPFs (E and F).
www.oncotarget.com
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there are few clinicopathological features that influence
outcome and no accurate biologic markers to predict the
clinical course or progression. As such, there is a pressing
need to identify new therapeutic targets and biomarkers
of disease biology. Given the recent literature suggesting
a role for ATRX in the pathogenesis and prognostication
for GBM [14] and other gliomas, [11, 15] including NF1related gliomas [16], our recent publication demonstrating
ATRX mutations in 2/7 MPNSTs sequenced [7], and the
reported correlation between ATRX immunostaining
and mutational status [15, 17, 18], we explored whether
or not ATRX expression was altered in a large subset of
MPNSTs.
Using IHC, we have demonstrated that 57% (43/74)
of MPNSTs have aberrant ATRX expression compared
to only 10% (2/21) of plexiform neurofibromas, and no
(0/9) atypical neurofibromas, benign precursor lesions
to MPNSTs. These data suggest that changes in ATRX
expression are associated with malignancy, but not
pre-malignant disease. This is in stark contrast to two
previously published studies of ATRX loss in a variety of
sarcoma subtypes [20, 21], which demonstrated loss of
ATRX in 1/17 (6%) and 2/47 (4%) of MPNST samples,
respectively. However, it should be noted that these
studies gave no breakdown of sporadic vs. NF1 associated
MPNST. In our study, 28 of 43 (65%) MPNSTs with

aberrant ATRX expression (mosaic or absent expression)
were NF1 associated (Table 2). Given that NF1-associated
MPNSTs represented 65% of our cohort, this may explain
the discrepancy. Furthermore, in the very recently
published TCGA analysis of the genetic and epigenetic
landscape of soft tissue sarcomas, 2 of the 5 MPNST
samples were noted to have copy number loss of the ATRX
locus (40%), a number more in line with the 60% aberrant
expression noted in the current study [22].
Most intriguingly, we found that there was a
significant decrease in overall survival for patients with
NF1-MPNSTs who have aberrant ATRX expression
(p = 0.04, log rank test) (Figure 4B), while there is no
difference in overall survival based on ATRX status for
sporadic MPNSTs (Figure 4C). Furthermore, ATRX
status also was found to independently predict overall
survival in our multivariate analysis of NF1-MPNSTs.
We know that the biology of NF1-MPNSTs is different
from that of sporadic MPNSTs as the survival is worse
for NF1-MPNSTs compared to sporadic MPNSTs [5, 23].
Additionally, different molecular features are seen in NF1
vs sporadic MPNSTs. For example, 88% of NF1-MPNSTs
exhibit loss of neurofibromin expression, but this is only
true for 43% of sporadic MPNSTs [24]. Similarly loss
of tri-methylation at lysine 27 of histone 3 (H3K27me3)
is seen in 95% of sporadic MPNSTs compared to only

Figure 2: Almost all plexiform neurofibromas show retained ATRX staining pattern. Low-power view of the routine

hematoxylin and eosin staining demonstrates typical plexiform neurofibroma morphology (A). The ATRX immunostain shows retained
nuclear staining (B). All atypical neurofibromas show retained ATRX staining pattern. A high-power view of the routine hematoxylin and
eosin staining demonstrates an atypical neurofibroma (C). The ATRX immunostain shows retained nuclear staining (D). The mitotic index
for the atypical neurofibroma in C and D is <1/50 HPFs.
www.oncotarget.com
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60% of NF1-associated MPNSTs [25]. Taken together
these data support the notion that the biology of NF1MPNSTs and sporadic MPNSTs is different and suggest
that aberrant ATRX expression may be cooperating with
some other alteration in NF1-MPNSTs leading to a poorer
prognosis for these tumors.
While ATRX is an X-linked tumor suppressor,
our data support the notion that it is a cooperating
mutation in both NF1-associated MPNSTs as well as

sporadic MPNSTs, rather than an initiating mutation in
tumorigenesis, as our data show a much higher percentage
of MPNSTs have aberrant expression by IHC versus
the precursor plexiform neurofibromas. In addition to
inactivation and loss of heterozygosity (LOH) via the usual
mechanisms (mutations, deletions, epigenetic silencing,
etc), X-linked tumor suppressors are also vulnerable to
inactivation via skewed X chromosomal inactivation and
bi-allelic epigenetic silencing in females, as either the

Figure 3: Higher percentage of MPNSTs show aberrant ATRX staining pattern compared to plexiform neurofibromas.

The number of cases with either retained or aberrant ATRX staining patterns are plotted. MPNSTs are depicted in panel (A) and plexiform
neurofibromas are depicted in panel (B). The percentage of MPNSTs with aberrant ATRX staining pattern is significantly different from
that of plexiform neurofibromas. (p = 0.0011, Fischer's Exact Test).
www.oncotarget.com
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Figure 4: Aberrant ATRX staining pattern (mosaic or negative) in MPNST correlates with worse survival in NF1
patients. (A) There is no significant survival difference with aberrant MPNST staining pattern in all MPNST patients. (p = 0.2091),
Kaplan-Meier analysis and log-rank test). (B) In NF1 patients, aberrant ATRX staining pattern in MPNSTs correlates with worse overall
survival. (p = 0.0276), Kaplan-Meier analysis and log-rank test) (C) In patients with sporadic MPNSTs, ATRX staining pattern does not
correlate with survival. (p = 0.4570), Kaplan-Meier analysis and log-rank test).

www.oncotarget.com
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Table 4: Multivariate overall survival analysis of NF1-MPNSTs
Parameter

P-value

Hazard ratio

ATRX(Aberrant vs. Retained)
Margin Status (Positive vs. Negative)
Metastasis at Diagnosis (Yes vs. No)
Adjuvant or Neoadjuvant Treatment (Yes vs No)
Age
Tumor Size (<5 cm or >5 cm)
Tumor location (extremity vs. non-extremity)
Gender

0.0158
0.0583
0.0009
0.6196
0.6654
0.2236
0.9895
0.9984

5.284
2.742
11.863
0.659
0.989
1.088
0.990
1.001

paternal or maternal X chromosome is wholly inactivated
during embryogenesis in each progenitor cell, and this is
passed on to its progeny, including differentiated daughter
cells [26]. Thus, on the surface, while it might seem as
though a sex bias would exist for ATRX, this is not seen
due to the fact that both males and females truly only
have one functioning copy of ATRX per cell, and thus
both sexes have an equal likelihood of developing LOH
or inactivating mutations in the one functional copy. This
is borne out by the data presented in Table 2, which shows
no statistically significant difference between sex and
ATRX staining pattern by Fisher’s exact test (p = 0.61).
Furthermore, it should be noted that individuals with
germline inactivating mutations or deletions in ATRX,
do not have a cancer predisposition syndrome, even in
the male population who manifest the alpha thalassemia/
mental retardation X-linked syndrome.
Given the marked difference in survival mentioned
above, future work will focus on whether reduced ATRX
expression results in a cell-autonomous growth advantage
in NF1-MPNSTs versus sporadic MPNSTs, and whether
such a difference requires NF1 loss or downstream
pathway activation. Furthermore, ATRX is also known
to direct members of the polycomb repressor complex 2
(PRC2) to target promoters and aid in heterochromatin
formation and epigenetic silencing [13]. Intriguingly,
recent reports have demonstrated a prominent association
of inactivating mutations in EED and SUZ12, two
members of the PRC2, with the development of both
sporadic and NF1-associated MPNSTs [27, 28]. We plan
to investigate whether or not ATRX also plays a role in
the epigenetic silencing of certain PRC2-targeted genes,
which may be amenable to future therapeutic strategies.
Finally, ATRX is also postulated to play a role in
the alternative lengthening of telomeres (ALT), which
is dependent on homologous recombination of sister
chromatids in G2/M phase or stalled replication forks
in S phase [29, 30]. Thus, future work will also hinge
on whether ATRX is aberrantly lost in other subtypes
of sarcomas as well as MPNSTs. For example, loss
of ATRX and subsequent activation of ALT has been
observed in liposarcomas and correlates with poor overall
www.oncotarget.com

95% Hazard ratio confidence
limits
1.367
20.433
0.965
7.792
2.758
51.026
0.127
3.425
0.940
1.040
0.950
1.246
0.228
4.306
0.299
3.352

survival [31]. However, its role in many other subtypes
of soft tissue sarcoma remains unclear. Changes in ATRX
expression, therefore, may be able to serve as a biomarker
for MPNSTs and even other types of sarcomas.
In summary, this study represents the first
comprehensive look at ATRX expression in MPNSTs.
Herein, we show that ATRX is aberrantly expressed in the
majority of MPNSTs and that this aberrant expression is
associated with poor overall survival in NF1-associated
MPNSTs, which suggests that ATRX expression could be
evaluated as a prognostic biomarker for these aggressive
sarcomas.

MATERIALS AND METHODS
Patient selection
This study was performed under active Human
Studies Protocols approved by the Institutional Review
Boards at each respective institution in accordance with
the 1964 Helsinki Declaration and its later amendments
or comparable ethical standards. Patients with a diagnosis
of malignant peripheral nerve sheath tumor (MPNST),
plexiform neurofibroma, or atypical neurofibroma
between 2011 and 2017 were retrieved from the
neurofibromatosis type 1 (NF1) patient database or the
sarcoma database from the Department of Hematology
and Oncology of Washington University in St Louis.
Patients with a diagnosis of NF1 had been followed in the
NF1 clinic. Patients called sporadic had either been seen
in the NF1 clinic and deemed not to have NF1, evaluated
by an NF1 specialist in the sarcoma clinic and deemed
not to have NF1, or had a well-documented skin exam,
musculoskeletal exam, and family history in the medical
record that would allow a physician to conclude that the
patient had no clinical diagnostic features of NF1. All cases
from Washington University were re-evaluated by one of
the authors (SD) in addition to the clinical pathologist
who made the initial diagnosis on the case. Whole tissue
sections from surgical excisions were evaluated for the 40
MPNST cases, 21 plexiform neurofibroma cases, and 9
atypical neurofibroma cases from Washington University.
23025
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Patients with MPNST diagnosed at UCSF were identified
from Anatomic Pathology archives between 1990 and
2012 for generation of a tissue microarray (TMA). A
chart review was performed at the time the TMA was
generated. If a clinical diagnosis of NF1 was made and
documented in the chart, the MPNST was deemed to be
NF1-associated. If the chart documentation stated that
there were no clinical features of NF1, the MPNST was
deemed to be sporadic. The previously-generated tissue
microarrays which included 34 patients treated at UCSF
were utilized in this study. The cores were obtained from
the most representative area of tumor and two 2 mm cores
from each tumor were evaluated. All cases chosen for
the TMA were evaluated by one of the authors (MP) as
well as two other pathologists at UCSF [32]. Information
on patients’ sex, age, NF1 status, and survival data were
obtained from the electronic medical record and Social
Security Death Index.

MPNST patients. The survival difference between groups
was compared using the log-rank test. Raw hazard ratios
(HR) and 95% CI were estimated from univariate Cox
model. A multivariate Cox proportional hazards model
was applied to compute adjusted HR and 95% CI after
adjusting for possible prognostic variables, including
margin status, adjuvant and neoadjuvant treatment, age,
initial tumor size, presence of metastasis at diagnosis,
initial location of the tumor, and gender. All tests were
two-sided and statistical significance was defined with
a p-value ≤ 0.05. Statistical analyses were performed
with SAS (version 9.4; SAS Institute, Cary, NC) unless
otherwise noted.

Abbreviations
MPNSTs: Malignant Peripheral Nerve Sheath
Tumors; ATRX: ATRX chromatin remodeler;
NF1-MPNSTs: NF1 associated MPNSTs; NF1:
Neurofibromatosis 1; NHEJ: Non-homologous end
joining; DSB: Double stranded DNA breaks; ALT:
Alternative Lengthening of telomeres; GBM: Gliobla
stoma; PRC2: Polycomb Repressor Complex 2;
H3K27me3: Histone 3 trimethylation at lysine 27; TMA:
Tissue microarray; CIs: Confidence Intervals.

ATRX immunohistochemistry and quantification
The hematoxylin and eosin–stained sections were
retrieved, and were reviewed to confirm the diagnosis.
Additional formalin-fixed paraffin-embedded sections
were obtained from the patient blocks at Washington
University in St. Louis. UCSF cases were evaluated on the
previously generated TMA. Immunohistochemical stain
for ATRX (Sigma, HPA001906, 1:300, rabbit polyclonal)
was performed with appropriate positive and negative
controls. The slides were reviewed blinded to the patients’
NF1 status. The percentage of tumor cells showing
nuclear ATRX labeling was evaluated. The ATRX IHC
was evaluated semi-quantitatively across the whole tumor
section used for staining. The staining results were scored
semi-quantitatively, defined as lost (0–20%), mosaic (21–
80%), and retained (81–100%). The mosaic and lost patterns
are grouped as aberrant ATRX expression in the analysis.
Mitotic index was evaluated from the most mitotically
active area of the tumor (Supplementary Table 2).
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any cause or date of last follow up. Date of death was
obtained from medical record or Social Security Death
Index, expiration note in chart or obituary. Kaplan-Meier
survival curves were generated for overall survival by
ATRX expression groups in NF1 MPNST and sporadic
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